Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

March 17, 2009 09:30 ET

Theralase Research Recognized by American Society of Laser Medicine and Surgery

TORONTO, ONTARIO--(Marketwire - March 17, 2009) - In October of 2008, Theralase Technologies Inc. (TSX VENTURE:TLT) announced new and independent scientific research, performed at University Health Network, demonstrating Theralase Technologies Super-Pulsed 905 nanometer (nm) laser technology's superior capabilities in aiding the healing of injured tissue.

The research has now been peer-reviewed and accepted for publication by the "American Society of Laser Medicine and Surgery" scientific journal. "The research, results and potential are remarkable and now its publication provides further credibility of Theralase's superior position in the marketplace." states Roger Dumoulin-White, President & CEO of Theralase Technologies.

The Theralase Super-Pulsed Laser has been scientifically proven to produce more nitric oxide than other tested laser sources. Production of nitric oxide has been shown to increase the diameter of blood vessels increasing blood flow and bringing much-needed oxygen and fuel molecules to injured tissue. This is significant in two ways: the control of inflammation and the acceleration of the natural healing processes.

"We are pleased to demonstrate that the Theralase Super-Pulsed Technology represents the best therapeutic laser on the market," says Dumoulin-White. "Our technology has now been proven to activate the cellular pathways that increase both energy to cells, as well as that which increases blood flow and reduces inflammation. By activating both pathways, the Theralase Super-Pulsed Laser provides superior efficacy when compared to the competition."

Kevin Wilk, a doctorate in physical therapy, a Clinical Director for Champion Sports Medicine and Vice President of Education for Physiotherapy, is regarded as one of the leading sports physical therapists in the U.S. and has been using the Theralase Super-Pulsed Laser Technology with outstanding results. "I consistently use the Theralase laser in our clinic numerous times per day. It's great for healing soft tissue injuries, damaged articular cartilage, muscle and tendon lesions. -I use it for many musculoskeletal conditions that I see at Champion Sports Medicine. I readily choose Theralase as a reliable and successful treatment source and my patients love the results."

Professional sports teams now utilizing the Theralase Technology, include the MLB's Toronto Blue Jays and Arizona Diamondbacks as well as the NBA's Toronto Raptors and Washington Wizards.

Theralase Secures Canada-Wide Distribution

Finally, Theralase Technologies is excited to announce a Canada-wide distribution agreement of the company's product line with Royal Cross, a well-established and respected distribution company for Canada's health care industry. This distribution agreement marks a significant step forward in the sales and marketing of Theralase Technologies full product line to medical professionals throughout Canada.

Scott Spencer, President of Royal Cross stated that, "We are delighted to be working with such a high caliber therapeutic laser designer and manufacturer as Theralase Inc. Their knowledge of the therapeutic laser industry is unsurpassed and their current and future product offerings are nothing short of ground breaking in the therapeutic laser world. With our strong distribution network and aggressive marketing programs, we are confident that we can help Theralase achieve its strategic objectives of accelerated product sales in the Canadian marketplace. We look forward to building upon our strongly established relationship for the benefit of both organizations."

Theralase Technologies Inc. is focused on a two-part strategy:

1. Production, marketing & distribution of the Theralase Super-Pulsed Laser for sale to health care practitioners and focused on the treatment of chronic pain, sports injuries & wounds.

2. Commercialization of cancer treatment through progressive research, clinical trials and advancement of new and exciting work in the direct destruction of cancers.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

Contact Information